Taiwan Biomaterial (6649) reported revenue of NT$12.4 million for Oct 2026, -34.1% year on year and -27.4% from the previous month. Revenue for Jan–Oct 2026 was NT$119.5 million (-38.1% year on year).
In Oct 2026, it ranked No. 131 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$12.4 million | -34.1% | -27.4% |
| Sep 2026 | NT$17 million | -49.3% | +18.0% |
| Aug 2026 | NT$14.4 million | -32.8% | +16.4% |
| Jul 2026 | NT$12.4 million | -30.3% | -5.8% |
| Jun 2026 | NT$13.1 million | +16.5% | +6.9% |
| May 2026 | NT$12.3 million | -9.9% | +7.0% |
| Apr 2026 | NT$11.5 million | +29.9% | -0.3% |
| Mar 2026 | NT$11.5 million | -38.2% | +60.0% |
| Feb 2026 | NT$7.2 million | -78.3% | -5.9% |
| Jan 2026 | NT$7.7 million | -51.5% | -54.5% |
| Dec 2025 | NT$16.9 million | +61.5% | +59.0% |
| Nov 2025 | NT$10.6 million | +18.8% | -43.5% |
| Oct 2025 | NT$18.8 million | +93.0% | -44.1% |
| Sep 2025 | NT$33.5 million | +435.7% | +56.2% |
| Aug 2025 | NT$21.5 million | +77.2% | +20.9% |
| Jul 2025 | NT$17.8 million | +95.0% | +57.4% |
| Jun 2025 | NT$11.3 million | +96.0% | -17.4% |
| May 2025 | NT$13.7 million | +44.0% | +54.3% |
| Apr 2025 | NT$8.8 million | +45.4% | -52.6% |
| Mar 2025 | NT$18.7 million | +220.7% | -43.7% |
| Feb 2025 | NT$33.2 million | +534.1% | +110.0% |
| Jan 2025 | NT$15.8 million | +106.9% | +51.4% |
| Dec 2024 | NT$10.4 million | +124.7% | +16.9% |
| Nov 2024 | NT$8.9 million | -11.6% | -8.2% |
| Oct 2024 | NT$9.7 million | +546.3% | +55.2% |
Jan–Oct 2026 cumulative: NT$119.5 million (-38.1% YoY)
Other Biotech & Medical companies
Compare with peers: Taiwan Biomaterial vs PEC / Taiwan Biomaterial vs Lotus Pharm / Taiwan Biomaterial vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16